Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01233609 · ClinicalTrials.gov registry record · Phase 2
Trial of Oral Valproic Acid for Retinitis Pigmentosa
A Phase 2 study of Retinitis Pigmentosa, sponsored by Foundation Fighting Blindness.
- Completed
- Registry status
- Phase 2
- Development phase
- 90
- Enrollment target
- 6
- Study locations
NCT01233609 is a Phase 2 study of Retinitis Pigmentosa that has completed, run by Foundation Fighting Blindness. The registered enrollment target is 90 participants, below the 259-participant average among 37 other Retinitis Pigmentosa trials with a reported enrollment target (65% lower). The trial reports 6 study locations across 6 states.
The verdict
NCT01233609, a Phase 2 study of Retinitis Pigmentosa, has completed, sponsored by Foundation Fighting Blindness.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 90 participants
- Enrollment target
- 6
- Study locations
Study Summary
The objectives of this study are to evaluate the efficacy of Valproic Acid (VPA) to both slow the progression of visual function loss and/or to restore visual function in patients with Autosomal Dominant Retinitis Pigmentosa (RP) and to collect safety and tolerability information.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Valproic Acid
Study Locations (6)
Florida
- University of Miami, Bascom Palmer Eye Institute - Miami
Michigan
- University of Michigan, Ann Arbor - Ann Arbor
Oregon
- Oregon Health & Science University - Portland
Tennessee
- University of Tennessee, Hamilton Eye Institute - Memphis
Texas
- Retina Foundation of the Southwest - Dallas
Utah
- University of Utah School of Medicine, Moran Eye Center - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2010-11 |
| Est. Completion | 2015-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01233609
The ClinicalTrials.gov registry entry for NCT01233609 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 259-participant average among 37 other Retinitis Pigmentosa trials with a reported enrollment target (65% lower). The listed sponsor is Foundation Fighting Blindness, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Retinitis Pigmentosa appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01233609 reports 6 study locations spanning 6 distinct geographic areas - top geographies include Florida, Michigan, Oregon.
Frequently Asked Questions
What is clinical trial NCT01233609 about?
NCT01233609 is a clinical study titled "Trial of Oral Valproic Acid for Retinitis Pigmentosa". The objectives of this study are to evaluate the efficacy of Valproic Acid (VPA) to both slow the progression of visual function loss and/or to restore visual function in patients with Autosomal Dominant Retinitis Pigmentosa (RP) and to collect safety and tolerability information.
What is the current status of trial NCT01233609?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 90 participants. The study started on 2010-11. Estimated completion is 2015-12.
What conditions does trial NCT01233609 study?
This clinical trial studies the following conditions: Retinitis Pigmentosa.
What interventions are being tested in trial NCT01233609?
The interventions under investigation include: Placebo (DRUG), Valproic Acid (DRUG).
Who is sponsoring clinical trial NCT01233609?
This trial is sponsored by Foundation Fighting Blindness, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01233609 being conducted?
This trial has 6 study locations across Florida, Michigan, Oregon, Tennessee, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Retinitis Pigmentosa
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Safety of a Single, Intravitreal Injection of 6.0M jCell (Famzeretcel) in Retinitis Pigmentosa (RP)
RECRUITING · Phase 2
-
Efficacy and Safety of MCO-010 Optogenetic Therapy in Adults With Retinitis Pigmentosa [RESTORE]
COMPLETED · Phase 2
-
Safety of Repeat Intravitreal Injection of Human Retinal Progenitor Cells (jCell) in Adult Subjects With Retinitis Pigmentosa
COMPLETED · Phase 2
-
Promising ROd-cone DYstrophy Gene therapY
RECRUITING · Phase 1
-
High Resolution Retinal Imaging
RECRUITING
-
Observational Study to Assess Endpoint Operational Feasibility & Measurement Properties in Patients with Retinal Degeneration
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.